


BETTER LONG-TERM DATA. PERIOD.

THE ONLY FDA APPROVED^{1,2} LONG-TERM RESULTS


AMENORRHEA RATE

(Zero bleeding)



SUCCESS RATE

(Normal, or less than Normal, bleeding)





LONG-TERM DATA

7X REDUCTION IN HYSTERECTOMY RATE^{1,2,3}

THE ONLY FDA APPROVED^{1,2} LONG-TERM RESULTS INCIDENCE OF HYSTERECTOMY

MINERVA ES
3 Years Follow-up

0.9%¹

Minerva Single Arm Study ¹ n=110	One Year		Three Years	
	# Patients	%	# Patients	%
Hysterectomy N (%)	0	0.0%	1	0.9%

NovaSure
3 Years Follow-up

6.3%²

NovaSure RCT Study ² n=175	One Year		Three Years	
	# Patients	%	# Patients	%
Hysterectomy N (%)	3	1.7%	11	6.3%

1. FDA Approved Labeling: Minerva Endometrial Ablation System [Operator’s Manual]. Redwood City, CA: Minerva Surgical, Inc; L0001 **2.** FDA Approved Labeling: NovaSure Impedance Controlled Endometrial Ablation System [Instructions For Use and Controller Operator’s Manual]. Marlborough, MA: Hologic, Inc; 2014. **3.** Not based on a head-to-head study